BioSpace News Archive

In February, just after the end of the quarter, we received feedback from the FDA, which means that we have a plan for our continued application process.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced interim Phase 1 clinical data for IDE397, a potential best in class methionine adenosyltransferase 2a inhibitor.

Anavex Life Sciences Corp. today announced the presentation of Phase 2 clinical biomarker data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at AD/PD™ 2022 International Conference on Alzheimer’s & Parkinson’s Diseases and related neurological disorders, taking place in Barcelona, Spain, and virtually on March 15–20, 2022.

Kamada Ltd., a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, issued the Letter to Shareholders from Amir London, Chief Executive Officer.

ASLAN Pharmaceuticals announced the appointment of Alex Kaoukhov, MD, as Chief Medical Officer based in ASLAN’s US office, effective immediately.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announces that it will be presenting data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

KAHR, today announced publication of preclinical data supporting the development of DSP107, a potential first-in-class investigational CD47x41BB targeting fusion protein designed to activate both the innate and adaptive immune systems, as a monotherapy and in combination for the treatment of cancer.

SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Ortho Regenerative Technologies Inc. today announced the appointment of Philippe Deschamps as its new Chief Executive Officer following the retirement of Mr. LeDuc, the Company’s CEO for the last three years.

Ginkgo Bioworks, the leading horizontal platform for cell programming, announced that management is scheduled to participate in a fireside chat at Jefferies Virtual Synthetic Biology Week, on March 22, 2022, at 10:00 a.m. Eastern Time.